Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease

Lucilla Parnetti, Davide Chiasserini, Emanuele Persichetti, Paolo Eusebi, Shiji Varghese, Mohammad M. Qureshi, Andrea Dardis, Marta Deganuto, Claudia De Carlo, Anna Castrioto, Chiara Balducci, Silvia Paciotti, Nicola Tambasco, Bruno Bembi, Laura Bonanni, Marco Onofrj, Aroldo Rossi, Tommaso Beccari, Omar Ali El-Agnaf, Paolo Calabresi

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

To assess the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD), we measured several proteins playing an important role in the disease pathogenesis. The activities of β-glucocerebrosidase and other lysosomal enzymes, together with total and oligomeric α-synuclein, and total and phosphorylated tau, were thus assessed in CSF of 71 PD patients and compared to 45 neurological controls. Activities of β-glucocerebrosidase, β-mannosidase, β-hexosaminidase, and β-galactosidase were measured with established enzymatic assays, while α-synuclein and tau biomarkers were evaluated with immunoassays. A subset of PD patients (n=44) was also screened for mutations in the β-glucocerebrosidase-encoding gene (GBA1). In the PD group, β-glucocerebrosidase activity was reduced (P<0.05) and patients at earlier stages showed lower enzymatic activity (P<0.05); conversely, β-hexosaminidase activity was significantly increased (P<0.05). Eight PD patients (18%) presented GBA1 sequence variations; 3 of them were heterozygous for the N370S mutation. Levels of total α-synuclein were significantly reduced (P<0.05) in PD, in contrast to increased levels of α-synuclein oligomers, with a higher oligomeric/total α-synuclein ratio in PD patients when compared with controls (P<0.001). A combination of β-glucocerebrosidase activity, oligomeric/total α-synuclein ratio, and age gave the best performance in discriminating PD from neurological controls (sensitivity 82%; specificity 71%, area under the receiver operating characteristic curve=0.87). These results demonstrate the possibility of detecting lysosomal dysfunction in CSF and further support the need to combine different biomarkers for improving the diagnostic accuracy of PD.

Original languageEnglish
Pages (from-to)1019-1027
Number of pages9
JournalMovement Disorders
Volume29
Issue number8
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

alpha-Synuclein
Synucleins
Parkinson Disease
Cerebrospinal Fluid
Glucosylceramidase
Enzymes
Hexosaminidases
Biomarkers
Mannosidases
Galactosidases
Mutation
Enzyme Assays
Immunoassay
ROC Curve

Keywords

  • Alpha-synuclein
  • Beta-glucocerebrosidase
  • CSF biomarkers
  • Lysosomal enzymes
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., ... Calabresi, P. (2014). Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Movement Disorders, 29(8), 1019-1027. https://doi.org/10.1002/mds.25772

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. / Parnetti, Lucilla; Chiasserini, Davide; Persichetti, Emanuele; Eusebi, Paolo; Varghese, Shiji; Qureshi, Mohammad M.; Dardis, Andrea; Deganuto, Marta; De Carlo, Claudia; Castrioto, Anna; Balducci, Chiara; Paciotti, Silvia; Tambasco, Nicola; Bembi, Bruno; Bonanni, Laura; Onofrj, Marco; Rossi, Aroldo; Beccari, Tommaso; Ali El-Agnaf, Omar; Calabresi, Paolo.

In: Movement Disorders, Vol. 29, No. 8, 2014, p. 1019-1027.

Research output: Contribution to journalArticle

Parnetti, L, Chiasserini, D, Persichetti, E, Eusebi, P, Varghese, S, Qureshi, MM, Dardis, A, Deganuto, M, De Carlo, C, Castrioto, A, Balducci, C, Paciotti, S, Tambasco, N, Bembi, B, Bonanni, L, Onofrj, M, Rossi, A, Beccari, T, Ali El-Agnaf, O & Calabresi, P 2014, 'Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease', Movement Disorders, vol. 29, no. 8, pp. 1019-1027. https://doi.org/10.1002/mds.25772
Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Movement Disorders. 2014;29(8):1019-1027. https://doi.org/10.1002/mds.25772
Parnetti, Lucilla ; Chiasserini, Davide ; Persichetti, Emanuele ; Eusebi, Paolo ; Varghese, Shiji ; Qureshi, Mohammad M. ; Dardis, Andrea ; Deganuto, Marta ; De Carlo, Claudia ; Castrioto, Anna ; Balducci, Chiara ; Paciotti, Silvia ; Tambasco, Nicola ; Bembi, Bruno ; Bonanni, Laura ; Onofrj, Marco ; Rossi, Aroldo ; Beccari, Tommaso ; Ali El-Agnaf, Omar ; Calabresi, Paolo. / Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. In: Movement Disorders. 2014 ; Vol. 29, No. 8. pp. 1019-1027.
@article{6cd47e0d84b243ce94b00fedf364c093,
title = "Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease",
abstract = "To assess the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD), we measured several proteins playing an important role in the disease pathogenesis. The activities of β-glucocerebrosidase and other lysosomal enzymes, together with total and oligomeric α-synuclein, and total and phosphorylated tau, were thus assessed in CSF of 71 PD patients and compared to 45 neurological controls. Activities of β-glucocerebrosidase, β-mannosidase, β-hexosaminidase, and β-galactosidase were measured with established enzymatic assays, while α-synuclein and tau biomarkers were evaluated with immunoassays. A subset of PD patients (n=44) was also screened for mutations in the β-glucocerebrosidase-encoding gene (GBA1). In the PD group, β-glucocerebrosidase activity was reduced (P<0.05) and patients at earlier stages showed lower enzymatic activity (P<0.05); conversely, β-hexosaminidase activity was significantly increased (P<0.05). Eight PD patients (18{\%}) presented GBA1 sequence variations; 3 of them were heterozygous for the N370S mutation. Levels of total α-synuclein were significantly reduced (P<0.05) in PD, in contrast to increased levels of α-synuclein oligomers, with a higher oligomeric/total α-synuclein ratio in PD patients when compared with controls (P<0.001). A combination of β-glucocerebrosidase activity, oligomeric/total α-synuclein ratio, and age gave the best performance in discriminating PD from neurological controls (sensitivity 82{\%}; specificity 71{\%}, area under the receiver operating characteristic curve=0.87). These results demonstrate the possibility of detecting lysosomal dysfunction in CSF and further support the need to combine different biomarkers for improving the diagnostic accuracy of PD.",
keywords = "Alpha-synuclein, Beta-glucocerebrosidase, CSF biomarkers, Lysosomal enzymes, Parkinson's disease",
author = "Lucilla Parnetti and Davide Chiasserini and Emanuele Persichetti and Paolo Eusebi and Shiji Varghese and Qureshi, {Mohammad M.} and Andrea Dardis and Marta Deganuto and {De Carlo}, Claudia and Anna Castrioto and Chiara Balducci and Silvia Paciotti and Nicola Tambasco and Bruno Bembi and Laura Bonanni and Marco Onofrj and Aroldo Rossi and Tommaso Beccari and {Ali El-Agnaf}, Omar and Paolo Calabresi",
year = "2014",
doi = "10.1002/mds.25772",
language = "English",
volume = "29",
pages = "1019--1027",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease

AU - Parnetti, Lucilla

AU - Chiasserini, Davide

AU - Persichetti, Emanuele

AU - Eusebi, Paolo

AU - Varghese, Shiji

AU - Qureshi, Mohammad M.

AU - Dardis, Andrea

AU - Deganuto, Marta

AU - De Carlo, Claudia

AU - Castrioto, Anna

AU - Balducci, Chiara

AU - Paciotti, Silvia

AU - Tambasco, Nicola

AU - Bembi, Bruno

AU - Bonanni, Laura

AU - Onofrj, Marco

AU - Rossi, Aroldo

AU - Beccari, Tommaso

AU - Ali El-Agnaf, Omar

AU - Calabresi, Paolo

PY - 2014

Y1 - 2014

N2 - To assess the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD), we measured several proteins playing an important role in the disease pathogenesis. The activities of β-glucocerebrosidase and other lysosomal enzymes, together with total and oligomeric α-synuclein, and total and phosphorylated tau, were thus assessed in CSF of 71 PD patients and compared to 45 neurological controls. Activities of β-glucocerebrosidase, β-mannosidase, β-hexosaminidase, and β-galactosidase were measured with established enzymatic assays, while α-synuclein and tau biomarkers were evaluated with immunoassays. A subset of PD patients (n=44) was also screened for mutations in the β-glucocerebrosidase-encoding gene (GBA1). In the PD group, β-glucocerebrosidase activity was reduced (P<0.05) and patients at earlier stages showed lower enzymatic activity (P<0.05); conversely, β-hexosaminidase activity was significantly increased (P<0.05). Eight PD patients (18%) presented GBA1 sequence variations; 3 of them were heterozygous for the N370S mutation. Levels of total α-synuclein were significantly reduced (P<0.05) in PD, in contrast to increased levels of α-synuclein oligomers, with a higher oligomeric/total α-synuclein ratio in PD patients when compared with controls (P<0.001). A combination of β-glucocerebrosidase activity, oligomeric/total α-synuclein ratio, and age gave the best performance in discriminating PD from neurological controls (sensitivity 82%; specificity 71%, area under the receiver operating characteristic curve=0.87). These results demonstrate the possibility of detecting lysosomal dysfunction in CSF and further support the need to combine different biomarkers for improving the diagnostic accuracy of PD.

AB - To assess the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD), we measured several proteins playing an important role in the disease pathogenesis. The activities of β-glucocerebrosidase and other lysosomal enzymes, together with total and oligomeric α-synuclein, and total and phosphorylated tau, were thus assessed in CSF of 71 PD patients and compared to 45 neurological controls. Activities of β-glucocerebrosidase, β-mannosidase, β-hexosaminidase, and β-galactosidase were measured with established enzymatic assays, while α-synuclein and tau biomarkers were evaluated with immunoassays. A subset of PD patients (n=44) was also screened for mutations in the β-glucocerebrosidase-encoding gene (GBA1). In the PD group, β-glucocerebrosidase activity was reduced (P<0.05) and patients at earlier stages showed lower enzymatic activity (P<0.05); conversely, β-hexosaminidase activity was significantly increased (P<0.05). Eight PD patients (18%) presented GBA1 sequence variations; 3 of them were heterozygous for the N370S mutation. Levels of total α-synuclein were significantly reduced (P<0.05) in PD, in contrast to increased levels of α-synuclein oligomers, with a higher oligomeric/total α-synuclein ratio in PD patients when compared with controls (P<0.001). A combination of β-glucocerebrosidase activity, oligomeric/total α-synuclein ratio, and age gave the best performance in discriminating PD from neurological controls (sensitivity 82%; specificity 71%, area under the receiver operating characteristic curve=0.87). These results demonstrate the possibility of detecting lysosomal dysfunction in CSF and further support the need to combine different biomarkers for improving the diagnostic accuracy of PD.

KW - Alpha-synuclein

KW - Beta-glucocerebrosidase

KW - CSF biomarkers

KW - Lysosomal enzymes

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84904427435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904427435&partnerID=8YFLogxK

U2 - 10.1002/mds.25772

DO - 10.1002/mds.25772

M3 - Article

VL - 29

SP - 1019

EP - 1027

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -